• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Andreas von Planta, Ph.D., Member of the Board of Directors

Andreas von Planta, Ph.D.

Board member since 2006

Nationality: Swiss | Year of birth: 1955

Andreas von Planta is a leading expert in corporate governance, corporate law and stock exchange regulation. He advises boards of public companies on corporate governance matters and is a sought-after speaker and writer on these topics. He has co-authored the Switzerland chapter of the International Comparative Legal Guide to Corporate Governance for many years.

Professional experience

  • Senior counsel, Lenz & Staehelin, Switzerland (2017–present)
  • Partner, Lenz & Staehelin, Switzerland (1988–2017)

Mandates

  • Board member, Helvetia Holding AG, Switzerland
  • Board member, A.P. Moller Finance SA, Switzerland
  • Board member, Helvetia Schweizerische Lebensversicherungsgesellschaft AG, Switzerland
  • Board member, Helvetia Schweizerische Versicherungsgesellschaft AG, Switzerland
  • Chairman, HSBC Private Bank (Suisse) SA, Switzerland
  • Chairman, HSBC Private Banking Holdings (Suisse) SA, Switzerland
  • Board member, Socotab Frana SA, Switzerland
  • Chairman of the regulatory board, SIX Swiss Exchange AG, Switzerland
  • Board member, Burberry (Suisse) SA, Switzerland
  • Chairman of the audit committee, International Road Transport Union, Switzerland
  • Board member, Raymond Weil SA, Switzerland (2007–2018)
  • Board member and former chairman, Clinique Générale-Beaulieu SA, Switzerland (2008–2016)
  • Board member and former chairman, Schweizerische National Versicherungs AG, Switzerland (1997–2015)
  • Board member, Holcim AG, Switzerland (2003–2014)

Education

  • Master of Laws, Columbia Law School, US
  • Bar examination, Switzerland
  • Doctorate in law, University of Basel, Switzerland
  • Licentiatus iuris, University of Basel, Switzerland

Key skills

  • Law/regulatory/risk management
  • Environmental, social and governance (ESG)

You are here

  1. Home ›
  2. Our Company ›
  3. Board of Directors

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.